secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2026-08-04T20:05:17+00:00
Accession:  0001193125-26-332767
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q2 revenue up 21% to $189.9M; net income falls to $0.41 EPS; raises FY guidance low end
--------------------------------------------------------------------------------

- Total revenue $189.9M (+21% YoY); product revenue $111.2M (+16%), service revenue $78.8M (+29%).
- Net income $14.7M ($0.41 diluted EPS) vs $0.92 prior year; adjusted net income $16.2M ($0.44 adjusted EPS).
- Raised low end of FY2026 revenue guidance (excl. PAD Aviation) to $737M-$757M.
- Completed strategic investment in PAD Aviation on July 1, 2026 to establish European organ transplant air logistics network.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000119312526332767/0001193125-26-332767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000119312526332767/tmdx-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-332767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer